Research from the laboratory of Ari M. Melnick, MD, Division of Hematology and Medical Oncology in the Department of Medicine at Weill Cornell Medical College, has resulted in a promising new combinatorial therapy for diffuse large B cell lymphoma, an aggressive and rapidly progressive cancer that affects approximately 21,000 new people each year. This research, published in The Journal of Clinical Investigation, may hold significant implications for patient survival rates. Click here to read the news release and summary of Dr. Melnick’s findings. Click here to read the research paper.
A Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL
Update: this study is closed to enrollment.
Researchers have begun to understand how reversible changes in expression of genes contribute to the development of cancer and allow cancer cells to become resistant to the effects of chemotherapy. These reversible changes are termed “epigenetics” since they do not involve mutations in genes themselves.
In this trial we are studying a combination of 2 drugs that may work by reversing epigenetic changes in patients with diffuse large B-cell lymphoma (DLBCL) that has not responded well to chemotherapy.